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Key points
 Previous studies in fetuses with intrauterine growth restriction (IUGR) have shown that
adrenergic dysregulation was associated with low insulin concentrations and greater insulin
sensitivity.
 Although whole-body glucose clearance is normal, 1-month-old lambs with IUGR at birth
have higher rates of hindlimb glucose uptake, which may compensate for myocyte deficiencies
in glucose oxidation.
 Impaired glucose-stimulated insulin secretion in IUGR lambs is due to lower intra-islet insulin
availability and not from glucose sensing.
 We investigated adrenergic receptor (ADR) β2 desensitization by administering oral ADRβ
modifiers for the first month after birth to activate ADRβ2 and antagonize ADRβ1/3. In IUGR
lambs ADRβ2 activation increased whole-body glucose utilization rates and insulin sensitivity
but had no effect on isolated islet or myocyte deficiencies.
 IUGR establishes risk for developing diabetes. In IUGR lambs we identified disparities in
key aspects of glucose-stimulated insulin secretion and insulin-stimulated glucose oxidation,
providing new insights into potential mechanisms for this risk.
Abstract Placental insufficiency causes intrauterine growth restriction (IUGR) and disturbances
in glucose homeostasis with associated β adrenergic receptor (ADRβ) desensitization. Our
objectives were to measure insulin-sensitive glucose metabolism in neonatal lambs with IUGR
and to determine whether daily treatment with ADRβ2 agonist and ADRβ1/β3 antagonists for
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1 month normalizes their glucose metabolism. Growth, glucose-stimulated insulin secretion
(GSIS) and glucose utilization rates (GURs) were measured in control lambs, IUGR lambs and
IUGR lambs treated with adrenergic receptor modifiers: clenbuterol atenolol and SR59230A
(IUGR-AR). In IUGR lambs, islet insulin content and GSIS were less than in controls; however,
insulin sensitivity andwhole-bodyGURwere not different from controls. Of importance, ADRβ2
stimulation with β1/β3 inhibition increases both insulin sensitivity and whole-body glucose
utilization in IUGR lambs. In IUGR and IUGR-AR lambs, hindlimb GURs were greater but
fractional glucose oxidation rates and ex vivo skeletal muscle glucose oxidation rates were lower
than controls. Glucose transporter 4 (GLUT4) was lower in IUGR and IUGR-AR skeletal muscle
than in controls but GLUT1 was greater in IUGR-AR. ADRβ2, insulin receptor, glycogen content
and citrate synthase activity were similar among groups. In IUGR and IUGR-AR lambs heart rates
were greater, which was independent of cardiac ADRβ1 activation. We conclude that targeted
ADRβ2 stimulation improved whole-body insulin sensitivity but minimally affected defects in
GSIS and skeletal muscle glucose oxidation. We show that risk factors for developing diabetes
are independent of postnatal catch-up growth in IUGR lambs as early as 1 month of age and are
inherent to the islets and myocytes.
(Resubmitted 29 July 2019; accepted after revision 28 October 2019; first published online 30 October 2019)
Corresponding author S. W. Limesand: School of Animal and Comparative Biomedical Sciences, The University of
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Introduction
Intrauterine growth restriction (IUGR) and early
catch-up growth predict later development of chronic
non-communicable metabolic disorders such as Type 2
diabetes and cardiovascular disease (Barker, 1990, 1993,
2002; Barker et al. 1993a, 2005, 2007; Soto et al.
2003; McMillen & Robinson, 2005; Whincup et al.
2008). Deficiencies in insulin secretion and insulin
sensitivity manifest early in children that were born
small-for-gestational-age (SGA) and eventually progress
into more pronounced metabolic pathologies that
characterize the metabolic syndrome (Barker et al. 1993b,
2002; Hofman et al. 1997; Li et al. 2001; Bazaes et al. 2004;
McMillen et al.2006, 2008; Eriksson, 2019).Recapitulating
the causal link between fetal growth restriction and
lifelong metabolic disorders in numerous experimental
models across a variety of species has implicated adaptive
developmental programming in response to placental
insufficiency as the underlying mechanism (Simmons
et al. 2001; Ford et al. 2007; Owens et al. 2007b;
Jimenez-Chillaron et al. 2009; Gatford et al. 2010; Wallace
et al. 2018; Chatmethakul & Roghair, 2019).
Fetuses with placental insufficiency experience
progressive nutrient and oxygen deprivation and
respondwith greater noradrenaline (norepinephrine) and
adrenaline (epinephrine) secretion (Greenough et al.
1990; Simonetta et al. 1997; Danielson et al. 2005;
Limesand&Rozance, 2017).We found thatwhenplacental
insufficiency was produced by maternal hyperthermia
in sheep, the resulting fetal hypercatecholaminaemia
inhibited insulin secretion and independently slowed
growth (Leos et al. 2010; Limesand et al. 2013;Macko et al.
2013, 2016;Davis et al. 2015). Throughout life, individuals
born SGA due to IUGR have less lean mass and reduced
muscle strength, which is worsened by slower muscle
accretion during infancy (Greenwood et al. 1998; Hediger
et al. 1998; Gale et al. 2001; Sayer et al. 2004; Kensara et al.
2005; Inskip et al. 2007; Yliharsila et al. 2007). Despite
less muscle mass, insulin sensitivity for glucose utilization
is greater in IUGR fetal sheep, as their whole-body net
glucose utilization rates are normal but plasma insulin
and glucose concentrations are lower (Limesand et al.
2007; Thorn et al. 2013). However, the fraction of
glucose utilized for oxidative metabolism is lower, which
complements previous findings that chronic adrenergic
receptor β (ADRβ) stimulation increases non-oxidative
glucose disposal (Scheidegger et al. 1984; Budohoski et al.
1987; Jensen et al. 2005; Limesand et al. 2007; Brown
et al. 2015). We found that greater insulin sensitivity for
glucose utilization persists in IUGR lambs at 2 weeks
of age, but their higher plasma lactate concentrations
may indicate that rates of glucose oxidation do not
recover, resulting in lactate production; these results are
similar to observations in children born SGA from IUGR
(Jornayvaz et al. 2004; Camacho et al. 2017). Furthermore,
glucose-stimulated insulin secretion (GSIS) was sub-
stantially greater in these IUGR lambs,whichweassociated
with compensatory adaptations to high catecholamines in
utero (Leos et al. 2010; Chen et al. 2014, 2017; Camacho
et al. 2017; Kelly et al. 2018). These findings indicate a
role for changes in ADRβ signalling that creates a post-
natal enhancement ofGSIS and insulin-stimulated glucose
utilization (Limesand & Rozance, 2017; Yates et al. 2018).
The three ADRβ isoforms are expressed in a
tissue-specific manner, and as G-protein coupled
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receptors, their persistent activation lowers their own
responsiveness (Collins et al. 1991; Wettschureck &
Offermanns, 2005). In near-term IUGR fetuses and in
3-week-old IUGR lambs, we have shown that expression
of ADRβ2 mRNA is downregulated in adipose tissue
and skeletal muscle (Chen et al. 2010; Yates et al.
2012a). This ADRβ2 deficiency could explain restricted
growth and muscle accretion in IUGR offspring because
stimulationwith ADRβ2 agonists repartitions nutrients in
growing animals to support anabolic protein accretion and
energy-producing oxidative pathways (Byrem et al. 1998;
Consolo et al. 2015; Cadaret et al. 2017). Furthermore,
deficiencies in glucose oxidation in IUGR fetal sheep and
in adult humans born SGA from IUGR coincide with
impaired proximal insulin signalling that may reflect the
loss of counter-regulatory effects of adrenergic signalling
(Hadcock et al. 1992; Morisco et al. 2005; Ozanne et al.
2005; Thorn et al. 2009). An interaction in signal trans-
duction pathways has been demonstrated for ADRβ2
and insulin receptors, and lower ADRβ2 concentrations
relative to ADRβ1 would favour inhibition of proximal
insulin signalling (Baltensperger et al. 1996; Wang et al.
2000; Castle et al. 2001; Brennesvik et al. 2005; Gavi et al.
2007). Because this ADRβ profile is still observed in young
lambs with IUGR at birth, we hypothesize that the ADRβ2
effects to inhibit insulin receptors and insulin signalling
continue postnatally even though insulin secretion is no
longer suppressed (Muhlhausler et al. 2009; Chen et al.
2010; Camacho et al. 2017).
Although multiple factors may contribute to glucose
intolerance, we postulate that selective desensitization
of ADRβ2 after persistent exposure to hyper-
catecholaminaemia in late gestation represents an
adaptive mechanism responsible for impaired skeletal
muscle growth and insulin-sensitive glucose metabolism.
Furthermore, previous studies of the fetal cardiovascular
system indicate that sustained high concentrations of
catecholamines lower ADRβ responsiveness in the heart
(Jones & Ritchie, 1978; Bassett et al. 1990; Bocking et al.
1995; Gardner et al. 2002). Therefore, we investigated
whether selective ADRβ1 and ADRβ3 antagonists
combined with an ADRβ2 agonist will normalize the
predicted adrenergic dysregulation and improve early
outcomes in growth, insulin secretion and action, and
cardiovascular parameters in young lambs thatwere IUGR
at birth.
Our objectives for this study were to determine
deficiencies in insulin-stimulated glucose metabolism
in 1-month-old lambs with IUGR at birth. We
tested the hypothesis that these lambs have impaired
GSIS and greater hindlimb glucose utilization rates.
Furthermore, we postulate that these limitations result
from intrinsic impairments for GSIS responsiveness
of islets and for skeletal muscle insulin-stimulated
glucose metabolism. Finally, we sought to determine
whether ADRβ2 activation via daily administration of
pharmaceutical ADRβ modifiers would increase insulin
sensitivity for glucose metabolism and growth in IUGR
lambs.
Methods
Ethical approval
Study protocols were approved by the Institutional
Animal Care and Use Committee at The University of
Arizona (Protocol no. 08-132) and follow the guidelines
from the American Association for the Accreditation
of Laboratory Animal Care International. All work
was conducted at the university’s Agricultural Research
Centre. Pregnant Columbia–Rambouillet crossbred ewes
were purchased from Nebeker Ranch (Lancaster, CA,
USA), and those carrying singleton pregnancies were
identified by ultrasonography prior to being assigned to an
experimental group. The ewes were 2–4 years of age with
unknown parity. Animals were managed as previously
described (Chen et al. 2010), and these pregnant ewes
(45 ± 2 kg) were assigned via simple randomization to
the thermoneutral control group (n= 16) or the placental
insufficiency-induced IUGR group (n = 30). Lambs born
from the placental insufficiency-induced IUGR group
(IUGR lambs) were produced using the maternal hyper-
thermia model (Chen et al. 2010; Camacho et al. 2017).
Briefly, pregnant ewes were exposed to elevated ambient
temperatures (40°C for 12 h; 35°C for 12 h; dew point
22°C) from 38 ± 1 to 87 ± 1 days of gestation. Control
lambs were from ewes that were maintained at 22 ± 1°C
and pair fed to the average ad libitum feed intake of the
hyperthermic ewe group. All sheep were given ad libitum
access to water and salt. One control and nine IUGR
fetuses were lost prior to birth for undiagnosed reasons,
leaving 15 controls and 22 IUGR lambs to be studied.
Ewes delivered naturally and lambs were removed from
the ewe to eliminate confounding maternal variability.
Lambs were ear tagged and housed in adjacent individual
pens in a separate location from their mothers. All lambs
were fed colostrum four to six times over the first 36 h
after birth before being reared solely on ad libitum milk
replacer (Milk Specialties Co., Dundee, IL, USA). Body
weight, crown–rump length (poll to tail head), hind-
limb length (hip to hoof) and head circumference were
measured at birth. The first seven IUGR lambs and six
control lambs born were pre-selected for postnatal studies
without being subjected to the postnatal intervention. The
remaining IUGR lambs were randomly assigned to also
receive either no postnatal intervention (IUGR; n = 14)
or to receive daily oral ADRβ modifiers (IUGR-AR,
n = 8). This daily treatment consisted of 20 µg kg−1 day−1
clenbuterol (ADRβ2 agonist), 400 µg kg−1 day−1 atenolol
(ADRβ1 antagonist) and 2 µg kg−1 day−1 SR59230A
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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(ADRβ3 antagonist), given orally in 50ml ofmilk replacer
(Coleman et al. 1988; MacRae et al. 1988; Manara et al.
1996; Torneke et al. 1998; Chiou et al. 2000; Despres et al.
2002; Kanzler et al. 2011; Miniaci et al. 2013). The doses
of clenbuterol, atenolol and SR59230A were chosen to
provide the lowest effective dose in order to minimize
potential off-target effects. Because of the prospective
nature of the study and application of hyperthermia before
the ability to determine fetal sex, the study did not take
into account the sex distribution.
Physiological studies to measure insulin secretion and
insulin sensitivity were performed on each lamb in no
particular order and separated by at least 1 day. Growth
rates were determined from body weights measured daily
from birth (day 0) to day 29 of age. Absolute growth rates
were linear over this period, and the R2 (coefficient of
determination) values of all slopes were 0.96 and not
different among experimental groups. Growth rates as a
percentage of birth weights were calculated by subtracting
birth weight from daily body weight and then dividing by
birth weight. Dry matter intake per gram of weight gained
was used to determine daily feed-to-gain efficiency for
each lamb (i.e. grams of milk consumed on a dry matter
basis per gram of weight gained).
Surgical preparation
At 24 ± 1 days of age, lambs (15 control, 14 IUGR
and 8 IUGR-AR) were fasted for 3–4 h. A jugular vein
was used to administer diazepam (0.2 mg kg−1) and
ketamine (20 mg kg−1) for induction, and the lambs
were intubated and maintained by inhalation of 1.5–4%
isoflurane in oxygen for the duration of the surgical
procedure. The depth of anaesthesia was determined
and maintained by response to touch, corneal reflex
and assessment of muscle tone, as well as continuous
pulse oximetry and heart rate monitoring. At induction,
lambs received an intramuscular injection of penicillin
G procaine injectable suspension (1350 units (U) kg−1;
Agri-Cillin, Huvepharma, Inc., Peachtree City, GA, USA).
In the non-study hindlimb, indwelling catheters (Tygon
ND-100-80FlexiblePlasticTubing; outerdiameter 1.4mm
and inner diameter 0.9 mm) were surgically placed in
the descending (abdominal) aorta and inferior vena cava
via the femoral artery and vein for blood sampling and
intravenous infusions. In the distal femoral vein of the
contralateral hindlimb, a catheter was placed with the
tip advanced to the external iliac vein and the deep
circumflex iliac artery and vein were ligated and severed
to isolate blood flow to the external iliac artery and vein.
This hindlimb was designated the study limb. A Precision
S-series Flow Probe (3 or 4 mm; Transonic Systems, Inc.,
Ithaca, NY, USA) was positioned around the external iliac
artery of the study limb. Prior to placement, catheters
were filled with heparinized saline (30 U ml−1, 0.9%
w/v NaCl, Nova-Tech, Inc., Grand Island, NE, USA).
After placement, the flow probe cable and the catheters
were tunnelled subcutaneously to the flank, exteriorized
through a skin incision, and kept in a plastic mesh pouch
sutured to the skin. Lambs were given post-operative
analgesics (0.01 g kg−1 body weight phenylbutazone)
for 3 days and allowed to recover before performing
studies. Catheters were flushed daily with heparinized
saline.
Insulin secretion responsiveness to glucose and
arginine
Glucose-stimulated insulin secretion (GSIS)was evaluated
with a square-wave hyperglycaemic clamp at 28 ± 1 days
of age as described previously (Camacho et al. 2017).
Briefly, lambs were fasted for 3 h and then placed
into the Panepinto sling. After approximately 20 min of
acclimation, basal (fasted) blood samples were collected
at −30, −11 and −2 min for plasma glucose, insulin,
cortisol, adrenaline andnoradrenalinemeasurements.The
hyperglycaemic clamp was initiated with an intravenous
dextrose bolus (250± 20 mg kg−1) followed by a constant
infusion of 33% (w/v) dextrose solution that was adjusted
to maintain arterial plasma glucose concentrations at
approximately twice the basal glucose concentration
observed for each lamb. Sample times are presented
relative to administration of the dextrose bolus (time= 0).
After the onset of the infusion, arterial blood samples were
collected every 5 min for a minimum of 20 min to ensure
that steady-state plasma glucose concentrations were
achieved. Afterward, three blood samples were collected
at approximately 30, 45 and 60 min. Steady-state hyper-
glycaemic conditions were considered to be confirmed
when glucose concentrations varied less than ±9%
from the overall mean. Acute, first-phase insulin
concentrations were calculated for the first 20 min of
hyperglycaemia and second-phase insulin concentrations
were calculated during the hyperglycaemic clamp
(30–60 min). Glucose-potentiated arginine-stimulated
insulin concentration was determined with a follow-on
arginine bolus (0.5 mmol kg−1) to the GSIS study.
One minute after the final GSIS sample was collected,
the dose of arginine was administered over a 4 min
period. Blood samples for plasma insulin concentrations
were collect at 5 and 15 min after administering
arginine.
Insulin sensitivity for glucose disposal rate
At 28 ± 1 days of age, glucose utilization rates
were measured under basal (fasted) conditions and
then again during a hyperinsulinaemic–euglycaemic
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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clamp as described previously (Camacho et al.
2017). Body weight-specific rates of glucose utilization
were determined by the net disappearance rate of
D-[14C-U]glucose (PerkinElmer Life Sciences, Boston,
MA, USA) during basal and hyperinsulinaemic
steady-state periods. Lambs were fasted for 3 h and then
placed into the Panepinto sling. A constant infusion
(2 ml h−1) of radiolabelled glucose (37.2 µCi ml−1) in
saline was initiated following a 4 ml priming bolus. After
40 min, four arterial blood samples were collected at
8–10 min intervals and used to measure basal glucose
utilization rates (µmol min−1 kg−1), plasma insulin,
glucose and lactate concentrations, and arterial blood
gases and oximetry. Hyperinsulinaemia was initiated with
a priming dose of insulin (175mU kg−1; HumulinR; Lilly;
Indianapolis, IN, USA) followed by a constant infusion at
0.5, 2 or 4 mU min−1 kg−1. Each lamb was studied at a
minimumof twohyperinsulinaemic periods. Euglycaemia
was concurrently maintained with a 33% (w/v) dextrose
infusion that was adjusted in response to arterial plasma
glucose concentrations measured every 5–10 min until
steady-state conditions were achieved, usually within an
hour. Euglycaemia was considered to be at a steady state
when arterial plasma glucose concentrations varied less
than±9%of thebasal periodmean.Arterial blood samples
were collected at 8–10 min intervals.
For lambs inwhichhindlimbvenous catheters remained
patent on the day of the study (n = 7 controls, 5 IUGR,
5 IUGR-AR), hindlimb glucose uptake and oxidation
rates were determined. Blood flow into the hindlimb
through the exterior iliac artery was measured with
the Transonic flow probe and recorded using LabChart
software (ADInstruments, Colorado Springs, CO, USA).
Venous blood samples from the study limb were collected
simultaneously with arterial blood samples. Aliquots of
arterial and venous whole blood samples were used
to determine blood [14C]glucose concentrations, blood
14CO2 concentrations, blood oxygen content, and plasma
glucose and lactate concentrations. Hindlimb glucose
oxidation rates weremeasured at 0mUmin−1 kg−1 (basal)
and 4 mU min−1 kg−1 hyperinsulinaemic–euglycaemic
periods.
Heart rate and blood pressure
To confirm the functional presence of orally administered
β2 agonist clenbuterol along with β1 antagonist atenolol
and β3 antagonist SR59230A we measured mean systemic
arterial blood pressures and heart rates by attaching an
externalized arterial catheter to a physiological pressure
transducer that was connected to a PowerLab 8/35 with
a bridge amplifier (ADInstruments Inc.). Pressures and
heart rates were determined on three separate days and
analysed with LabChart software. Pressure transducers
were calibrated with a mercury column manometer.
Lambs were placed in the sling and physiological pressure
transducers were set to the height of the heart. After an
acclimation period of at least 10 min, data were recorded
for a minimum of eight consecutive minutes under basal
conditions. At 29 ± 1 days of age, lambs were challenged
with the ADRβ1 agonist dobutamine HCl (12.5 mg ml−1;
Hospira, Inc., Lake Forest, IL, USA) to evaluate cardiac
responsiveness (Stephens et al. 2011). Data were recorded
for 15 min during both basal and dobutamine-stimulated
(10 µg min−1 kg−1) periods.
Biochemical analysis and calculations
Plasma glucose and lactate concentrations were measured
with a YSI 2700 Select Biochemistry Analyzer
(Yellow Springs Instruments, Yellow Springs, OH,
USA). Blood gases and oximetry were measured
in whole blood collected in heparin-lined syringes
(Elkins-Sinn, Cherry Hill, NJ, USA) using an ABL720
(Radiometer, Copenhagen, Denmark). Values were
temperature-corrected for the rectal temperature of
the lamb measured at the start of the study. Whole
blood [14C]glucose was determined in supernatants after
being deproteinized by mixing whole blood with 0.3 N
zinc sulfate heptahydrate and 0.3 M barium hydro-
xide. The supernatant was separated into triplicate
aliquots and dried. Radioactivity was measured with a
LS 6500 Multi-Purpose Scintillation Counter (Beckman
Coulter, Fullerton, CA, USA) in Hionic Fluor Liquid
Scintillation Cocktail (PerkinElmer Inc., Waltham, MA,
USA). Plasma hormone concentrations were determined
by enzyme-linked immunosorbent assay (ELISA) for
insulin (Ovine Insulin ELISA; ALPCO Diagnostics,
Windham, NH, USA; sensitivity 0.14 ng ml−1 intra-
and interassay coefficients of variation, 3% and 6%,
respectively), cortisol (Oxford Biomedical Research,
Oxford, MI, USA; sensitivity 10 pg ml−1; intra- and inter-
assay coefficients of variation, 9% and 12%, respectively),
noradrenaline (Labor Diagnostika Nord, Nordhorn,
Germany; sensitivity, 25 pg ml−1; intra- and inter-
assay coefficients of variation, 6% and 14%, respectively)
and adrenaline (Labor Diagnostika Nord; sensitivity,
8.3 pgml−1; intra- and interassay coefficients of variation,
11% and 17%, respectively). The 14CO2 was released from
triplicate aliquots of whole blood with 2 N HCl, captured
in Solvable (PerkinElmer Inc.), and measured in Ultima
Gold scintillation cocktail (PerkinElmer Inc.).
Whole-body net glucose utilization rates (µmolmin−1)
were calculated as the ratio of [14C]glucose infusion
rate (d.p.m. min−1) to arterial whole blood [14C]glucose
specific activity (d.p.m. µmol−1 glucose). Endogenous
(hepatic) glucose production rates were calculated as the
difference between the whole-body net glucose utilization
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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rate and exogenous dextrose (D-glucose) infusion rate
(µmol min−1). All rates were normalized to body
weight (kg). Insulin sensitivity for glucose utilization
rate (µmol min−1 kg−1 µg−1 l−1) was calculated as
the body weight-specific net glucose utilization rate
(µmol min−1 kg−1) divided by the arterial plasma insulin
concentration (µg l−1).
Hindlimb metabolic flux calculation
Mean hindlimb glucose, lactate, [14C]glucose and
14CO2 fluxes were calculated from the simultaneously
collected femoral arterial and venous blood sample
pairs. Weight-specific net uptake rates of oxygen,
[14C]glucose and glucose as well as outputs of lactate
were calculated by the Fick principle as the product of
artery blood flow and arteriovenous difference (Rozance
et al. 2018). Arterial blood [14C]glucose concentrations
(d.p.m. ml−1) were divided by arterial blood glucose
concentrations (µmol ml−1) to determine specific activity
(d.p.m. µmol−1). All net hindlimb uptakes and output
rates were normalized to hindlimb weight (kg) measured
at necropsy. Glucose and lactate oxygen quotients were
calculated as six or three times, respectively, the ratio of
the arteriovenous difference of the respective carbohydrate
to the arteriovenous difference of oxygen. The fractional
extraction (%) of glucose across the hindlimb was
calculated as the arteriovenous difference in plasma
glucose concentration divided by the arterial plasma
glucose concentration.
Post-mortem
Lambs were killed at 31 ± 1 days with an intravenous
overdose of sodium pentobarbital (86 mg kg−1) and
phenytoin sodium (11 mg kg−1; Euthasol; Virbac Animal
Health). At necropsy, pancreatic ducts were perfused
with a collagenase solution (0.5 mg ml−1 Collagenase V,
Sigma-Aldrich, St Louis,MO,USA; 0.02%DNase I, Roche,
Indianapolis, IN, USA; in Krebs–Ringer buffer (KRB),
118 mmol l−1 NaCl, 4.8 mmol l−1 KCl, 25 mmol l−1
NaHCO3, 1.2 mmol l−1 MgSO4, 1.2 mmol l−1 KH2PO4,
2.5 mmol l−1 CaCl2) as described previously (Limesand
et al. 2006). Thepancreaswas removedbyblunt dissection,
submerged in the collagenase solution, and incubated at
37°C for 20 min with gentle mixing every 3 min for islet
isolation. Organs (brain, liver, heart, kidneys and lungs)
and perirenal adipose tissue were dissected and weighed.
Mid-sections of semitendinosus, semimembranosus and
bicep femoris muscles were collected for cell isolation
or were frozen. The study limb was disarticulated at the
proximal end of the femur and weighed. Tissue samples
were snap-frozen in liquid nitrogen and stored at −80°C
for enzyme and immunoblot analysis.
Pancreatic islet isolation and functional assessments
Digested pancreas tissue was filtered through a 500 µm
mesh filter and was washed three times by sedimentation
in KRB containing 0.5% bovine serum albumin (BSA).
Pancreas tissue that did not pass through the mesh
filter was subjected to an additional 20 min digestion
in collagenase solution and then filtered and washed.
Islets were partially purified with a discontinuous
gradient of polysucrose 400 (Corning cellgro, Corning,
NY, USA) diluted with Hank’s balanced salt solution
(Gibco HBSS; Thermo Fisher Scientific, Waltham, MA,
USA) to 25%, 23%, 20% and 11% dilutions. After
being centrifuged at 1400 g for 20 min, islets were
removed from the 20% layer and were washed three
times in KRB–BSA. Islets were incubated overnight in
RPMI 1640 (Sigma-Aldrich) supplemented with 5% fetal
bovine serum and penicillin–streptomycin–neomycin
(0.1 mg ml−1 − 0.1 mg ml−1–0.2 mg ml−1) at 37°C in
95% O2 − 5% CO2.
Islets were incubated for 60 min in KRB–BSA prior
to functional assessments. Islets (200 per lamb) from
each lamb were re-suspended in Media 199 (Corning
Mediatech, Inc., Tewksbury, MA, USA) that had been
pre-warmed to 37°C and were divided evenly between
three chambers of a Fluorescence Lifetime Micro Oxygen
Monitoring System (Instech Laboratories, Inc., Plymouth
Meeting, PA, USA) (Papas et al. 2007; Smith et al. 2017).
Measurements of partial pressure of O2 (PO2) in each
chamber were recorded over time using fibre optic sensors
and NeoFox viewer software (Instech Laboratories, Inc.).
Oxygen consumption rates (OCRs; nmol O2 min−1) were
determined from the slope of PO2 disappearance over
time and normalized to the DNA content of islets in each
chamber (OCR/DNA; nmolO2 min−1 (mgDNA)−1). Islet
DNA was extracted with a 1 N ammonium hydroxide
and 0.2% Triton X-100 solution and DNA content was
determined in triplicate with Quant-iT PicoGreen dsDNA
kit (Thermo Fisher Scientific) according to manufacturer
instructions. Oxygen consumption rates were measured
in control and IUGR islets only.
Insulin secretion from isolated islets was measured
by perifusion (Biorep Technologies Perifusion System,
Peri-4.2; Miami Lakes, FL, USA). GSIS was measured in
triplicate with 75 islets per perifusion chamber at a flow
rate of 100 µl min−1. KRB–BSA that was supplemented
with glucose (0.5 or 11.1 mmol l−1) or KCl (30 mmol l−1
with 1.1 mmol l−1 glucose), pre-warmed to 37°C, and
oxygen-saturated (95% O2–5% CO2) was used in islet
perifusions. Following a 40 min baseline period at
0.5 mM glucose, islets were stimulated for 40 min with
11.1 mmol l−1 glucose (GSIS) and subsequently with
KCl–glucose (maximal response). Samples were collected
and stored at−80°C, and insulin concentrationswere sub-
sequently measured with an ovine insulin ELISA. First
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phase insulin secretion was determined over the first
11 min of high glucose and second phase insulin secretion
was determined between 20 and 40 min by calculating
the area under the curve for these time frames. Islet
preparations that were unresponsive to KCl stimulation
were excluded from the analysis. Islet insulin contentswere
determined in five replicates of 10 islets as described pre-
viously (Limesand et al. 2006).
Ex vivo skeletal muscle glucose oxidation rates
Longitudinal strips of semitendinosus muscle (6 technical
replicates per condition for each lamb) were iso-
lated and glucose oxidation rates were determined as
described previously (Cadaret et al. 2017) with some
modifications. Muscle strips (30–50 mg) were dissected,
mounted in Plexiglas U-clamps, and placed in 6-well
plates (Costar, Corning Inc., Kennebunk, ME, USA).
Muscle strips were pre-incubated for 1 h at 37°C
(95% O2: 5% CO2) in oxygen-saturated Krebs–Henseleit
bicarbonate buffer (KHB, pH 7.4) supplemented with
0.1% BSA, 5 mmol l−1 D-glucose and 32 mmol l
D-mannitol (Sigma-Aldrich). Muscle strips were then
incubated in KHB media containing no added hormones
(basal), insulin (10 µU ml−1 Humulin R), insulin +
catecholamines (12.5 µmol l−1 adrenaline,12.5 µmol l−1
noradrenaline), or insulin+ cytochalasin B (20mmol l−1;
Sigma-Aldrich) for 30 min. Finally, muscle strips were
incubated for 1 h in the above treatment media
supplemented with D-[14C-U]glucose (2 µCi ml−1). Glass
microfibre filters (Whatman GF/D; GE Healthcare Life
Sciences, Little Chalfont, UK) were saturated with 1 M
NaOH and suspended over each well of the plate, which
was sealed with a plastic gasket. After 1 h, 1 N HCl
was injected into each well. Plates were incubated for
2 h at room temperature, the filter papers were removed
and radioactivity from captured 14CO2 was measured
via liquid scintillation in Biosafe II Scintillation cocktail
(Research Products International Corp., Mount Prospect,
IL, USA). Muscle strips were removed from clamps and
weighed. Specific activity for glucose (d.p.m. pmol−1) was
determined and data are expressed as picomoles per milli-
gram of tissue per hour.
Skeletal muscle glycogen content, citrate synthase
activity and immunoblots
Glycogen contents and citrate synthase activities were
determined in semitendinosus muscles collected at
necropsy as described previously (Camacho et al. 2017).
Glucose concentrations from the extracted glycogen were
determined in triplicate, and results are expressed asmilli-
grams of glucose per gram of tissue (wet weight). Citrate
synthase activity was measured with the citrate synthase
assay kit (Sigma-Aldrich) from 20 µg of protein and are
expressed as activity per microgram of protein.
Immunoblots were performed on protein lysates
prepared from semitendinosus muscle (30–40 mg)
with CelLytic MT Cell Lysis Reagent (Sigma-Aldrich)
and protease inhibitors (0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 2 µg ml−1 Aprotinin, 2.5 µg ml−1
Leupeptin) as described previously (Camacho et al. 2017).
Primary antibodies used were raised in rabbit against
glucose transporter 1 (GLUT1, 1:250, Millipore Cat. no.
07-1401, lot no. 2630748, RRID:AB_1587074), glucose
transporter 4 (GLUT4, 1 µg ml−1, Sigma-Aldrich Cat. no.
G4048, lot no. 016M4809V, RRID:AB_1840900), ADRβ2
(ADRB2; 1:250, Santa Cruz Biotechnology Cat. no.
sc-569, lot no. G3115, RRID:AB_630926), insulin receptor
β-subunit (INSR, 1:250, Santa Cruz Biotechnology Cat.
no. sc-711, lot no. H0916, RRID:AB_631835) and
Tubulin-β (TUBB; 1:1000, Thermo Fisher Scientific
no. RB-9249-P0, lot no. 9249P1507B and 9249P1603L,
RRID:AB_722289). Antibody complexes were detected
with anti-rabbit IgG horseradish peroxidase conjugated
secondary antibody (1:15,000; Bio-Rad Laboratories,
Hercules, CA, USA) and chemiluminescence (West Pico
Chemiluminescent Substrate; Thermo Fisher). Protein
concentrations were quantified using photographed
images and densitometry analyses (Scion Image Software,
Frederick, MD, USA). Protein loading was normalized
with Tubulin-β concentrations. To accommodate the
number of samples, two immunoblots were run
simultaneously that contained overlapping samples for
internal controls. Data are presented as percentage of the
control mean.
Statistical analysis
Lamb morphometric characteristics, citrate synthase
activity, glycogen content, protein expression, arterial
blood pressure, heart rate and dobutamine responses
were analysed by ANOVA for group effects using
the MIXED procedure of SAS 9.4 (SAS Institute,
Cary, NC, USA). Differences were determined with
a post hoc Fisher’s least significant difference test.
Growth rates and growth rates/birth weights were
examined using repeatedmeasures analysis of theMIXED
procedure. Factors included in the repeated measure
models were experimental group, time (day) and their
interaction. Means were separated using the PDIFF
option of the LSMEANS statement of SAS. The GSIS
and arginine-stimulated insulin secretion studies were
analysed by ANOVA using the MIXED procedure. The
model included experimental groups (control, IUGR and
IUGR-AD), draw time, and their interaction. Appropriate
(minimize information criterion) covariance structures
were selected using the best fit statistics. In vivo rates
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Table 1. Birth morphometry
Group (n) Control (15) IUGR (14) IUGR-AR (8)
Sex (M:F) 9:6 3:11 2:6
Gestational age (day) 151 ± 1a 149 ± 1b 148 ± 1b
Birth weight (kg) 4.3 ± 0.2a 2.9 ± 0.3b 2.5 ± 0.4b
Crown–rump length
(cm)
49.7 ± 1.0a 43.3 ± 1.6b 41.6 ± 1.9b
Hindlimb length (cm) 40.9 ± 1.8 36.8 ± 2.2 38.6 ± 3.6
Head circumference
(cm)
24.9 ± 0.7 22.4 ± 0.9 20.7 ± 0.8
Head circumference/
weight
5.9 ± 0.2a 8.5 ± 0.7b 9.5 ± 1.1b
Animal numbers (n) within groups are presented in parentheses.
Data are expressed as the mean ± SEM. Differences (P < 0.05)
between groups are identified with different superscript
letters.
and fluxes were analysed by ANOVA using the MIXED
procedure with lamb as the random effect. Main effects
were experimental group (control, IUGR and IUGR-AR
lambs), study period defined by the insulin infusion
rate (basal and hyperinsulinaemia) and their interaction.
Ex vivo muscle glucose oxidation rates were analysed
by ANOVA with the MIXED procedure for effects of
experimental group, media condition (basal, insulin,
insulin + catecholamines, or insulin + cytochalasin B),
and their interaction. Themain effect of sex was not tested
due to insufficient power in the IUGR and IUGR-AR
groups. Means were separated using the Fisher’s least
significant difference test and were considered significant
when α 0.05. In the absence of interactions (P > 0.05),
significant main effects are reported; otherwise, inter-
active means are discussed. Lamb was considered the
experimental unit for all outputs. Data are presented as
the mean ± standard error of the mean.
Results
Morphometry at birth and postnatal growth
Morphometric measurements at birth, sex ratios
and gestational lengths for lambs are presented in
Table 1. At birth, IUGR and IUGR-AR lambs were
lighter, had shorter crown–rump lengths, and had
reduced head circumference-to-body weight ratios than
controls.
Control lambs were heavier than IUGR and IUGR-AR
lambs throughout the 30-day period (Fig. 1A). Absolute
growth rates were greater (P < 0.01) in control lambs
(292 ± 14 g day−1) than in IUGR (209 ± 17 g day−1)
or IUGR-AR (175 ± 19 g day−1) lambs, but IUGR and
IUGR-AR growth rates were not different from each
other. Growth as a percentage of birth weight was not
different among groups (Fig. 1B). Feed-to-weight gain
efficiencies were not different among groups (0.77± 0.04,
0.78 ± 0.04 and 0.81 ± 0.05 g g−1 for control, IUGR
and IUGR-AR lambs, respectively). At 28 ± 1 days of age,
IUGR (8.4 ± 0.6 kg) and IUGR-AR (6.9 ± 1.0 kg) lambs
weighed less (P< 0.05) than control lambs (12.5± 0.5 kg).
Cardiovascular measurements
Cardiovascular measurements were conducted to
confirm the functional presence of administered
ADRβ pharmacological modulators. Mean arterial blood
pressure was not different among experimental groups
(Fig. 2A). Resting heart rate was higher in IUGR
and IUGR-AR lambs compared to control lambs
(Fig. 2B). Administration of the ADRβ1 agonist
dobutamine increased heart rates in control lambs by
118 ± 15 beats min−1 from basal, which was of greater
magnitude (P < 0.05) than the 73 ± 15 beats min−1
increase in IUGR lambs. There was no response to
dobutamine in IUGR-AR lambs, which was expected due
to the ongoing oral administration of theADRβ1 inhibitor
atenolol (Fig. 2C).
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Figure 1. Lamb growth
A, average daily weights are presented for control (n = 15), IUGR
(n = 14) and IUGR-AR (n = 8) lambs. B, daily weights as a percentage
of birth weight are presented for lambs in each experimental group.
Different letters on the right side of A indicate group differences.
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Glucose- and arginine-stimulated insulin
concentrations
Fasting plasma glucose concentrations were not different
among groups, and glucose and insulin concentrations
increased (P < 0.05) during the hyperglycaemia clamp
(Fig. 3). Fasting plasma insulin concentrations were lower
in IUGR lambs compared to control lambs, but there was
no difference between IUGR and IUGR-AR groups. For
first-phase GSIS, glucose concentrations were greater in
IUGR-AR lambs compared to IUGR and control lambs,
whereas, first-phase insulin concentrations were lower in
IUGR and IUGR-AR lambs compared to control lambs.
For second-phase GSIS, glucose concentrations remained
greater in IUGR-AR lambs compared to IUGRand control
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Figure 2. Mean arterial blood pressure and heart rates
Mean arterial pressure (A) and heart rate (B) are presented for
control (n = 12; 7 male (M)/5 female (F)), IUGR (n = 14; 3M/11F)
and IUGR-AR (n = 7; 1M/6F) lambs. Dobutamine response (C) was
calculated as the difference in heart rate between stimulated and
unstimulated periods for control (n = 4; 3M/1F), IUGR (n = 4;
2M/2F) and IUGR-AR (n = 7; 1M/6F) lambs. Differences (P < 0.05)
between experimental groups are indicated by different letters.
lambs, but not different between IUGR and control
lambs. Second-phase insulin concentrations remained
lower in IUGR lambs compared to control lambs, but
insulin concentrations in IUGR-AR lambs were inter-
mediate to control and IUGR lambs. Glucose-potentiated
arginine-stimulated insulin concentrations were similar
among experimental groups (mean values for controls
31.8± 5.2µg l−1, IUGR lambs 30.7± 4.5µg l−1, IUGR-AR
lambs 27.4 ± 5.3 µg l−1).
Plasma cortisol concentrations were greater in
IUGR-AR lambs compared to IUGR and control
lambs (Table 2). Plasma adrenaline and noradrenaline
concentrations were not different among groups.
Whole-body insulin sensitivity for glucose utilization
The dose–response relationship between plasma insulin
concentrations and whole-body net glucose utilization
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Figure 3. Glucose stimulated insulin concentrations
Square-wave hyperglycaemic clamps were performed in control
(n = 12; 7M/5F), IUGR (n = 13; 3M/10F) and IUGR-AR (n = 7;
1M/6F) lambs at 28 days of age. Mean (±SEM) plasma glucose (A)
and insulin (B) concentrations are presented for basal (fasting),
first-phase (0–15 min) and second-phase (20–60 min) periods of the
GSIS study. The different letters above the bars represent significant
difference between means (P < 0.05).
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Table 2. Plasma cortisol and catecholamine concentrations
Group (n) Control (12) IUGR (13) IUGR-AR (7)
Cortisol (µg l−1) 22.8 ± 5.9a 24.4 ± 5.6a 46.2 ± 7.4b
Adrenaline (ng l−1) 109 ± 37 131 ± 17 102 ± 28
Noradrenaline (ng l−1) 573 ± 80 1076 ± 337 842 ± 304
Animal numbers (n) within groups are presented in parentheses.
Data are expressed as the mean ± SEM. Differences (P < 0.05)
between groups are identified with different superscript letters.
Plasma samples were collected during the basal period of the
GSIS study.
rates was best fitted (R2 = 0.64) by the Michaelis–Menten
equation shown in Fig. 4, which estimated insulin
responsiveness (maximum glucose utilization rate) at
65 ± 2 µmol min−1 kg−1 and insulin sensitivity
(insulin concentration needed for half-maximum glucose
utilization rate) at 1.0 ± 0.1 µg l−1. Lambs from
control and IUGR groups had similar blood glucose
concentrations under all conditions (6.0± 0.2 mmol l−1).
Plasma insulin concentrations and body weight-specific
net glucose utilization rates used to generate the
dose–response curves were not different between control
(Vmax 68 ± 3 µmol min−1 kg−1, Km 1.3 ± 0.2 µg l−1)
and IUGR lambs (Vmax 63 ± 3, Km 0.9 ± 0.2) at any
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Figure 4. Whole-body glucose utilization rate dose–response
to insulin
Body weight-specific net glucose utilization rates were determined in
control (n = 14; 8M/6F) and IUGR (n = 14; 3M/11F) lambs at 28 days
of age. No differences were found between IUGR and control
groups, and all lambs were combined to evaluate the dose–response
relationship. Glucose utilization rates were measured at basal and
three hyperinsulinaemic–euglycaemic periods by infusing insulin at
0.5, 2 and 4 mU min−1 kg−1. Each lamb was evaluated at two or
three steady-state periods. Insulin concentrations (µg l−1) are plotted
on the x-axis and net glucose utilization rates (µmol min−1 kg−1) on
the y-axis. A Michaelis–Menten equation (R2 = 0.64) was used to
predict maximum rate of glucose utilization
(65 ± 2 µmol min−1 kg−1) and half-maximum insulin concentration
(1.0 ± 0.1 µg l−1) for glucose utilization rate in lambs.
infusion rate, and these two groups were combined to
analyse this relationship. Plasma insulin concentrations
also did not differ between basal and 0.5 mU min−1 kg−1
infusion rates (1.5 ± 0.2 and 3.1 ± 1.2 µg l−1,
respectively) among groups. However, plasma insulin
concentrations increased (P < 0.01) sequentially at 2
and 4 mU min−1 kg−1 infusion rates (8.4 ± 1.3 and
20.5 ± 3.2 µg l−1, respectively). Whole-body glucose
utilization rates increased (P  0.05) sequentially from
the basal period (35 ± 1 µmol min−1 kg−1) to each
subsequent insulin infusion rate at 0.5 mU min−1
kg−1 (39 ± 2 µmol min−1 kg−1), 2 mU min−1 kg−1
(52 ± 2 µmol min−1 kg−1) and 4 mU min−1 kg−1
(65 ± 2 µmol min−1 kg−1).
Basedon thedose–response curve, insulin infusion rates
of 2 and 4 mU min−1 kg−1 were evaluated to determine
insulin sensitivity for whole-body net glucose utilization
rates. No interactions were found between groups or
insulin infusion rate for glucose concentrations, insulin
concentrations, glucose utilization rates, or endogenous
glucose production rates, which indicates that all lambs
had similar responses to the increased insulin infusion
rates. Blood glucose concentrations were not different
among all groups or between the different insulin infusion
rates (Fig. 5A). Plasma insulin concentrations were not
different among groups within any infusion period, but
average insulin concentrations across all groups increased
(P< 0.01) frombasal (1.5± 0.2µg l−1), as expected, when
insulinwas infused at 2mUmin−1 kg−1 (10.0± 1.7µg l−1)
and 4 mU min−1 kg−1 (26.2 ± 4.5 µg l−1; Fig. 5B).
Regardless of the insulin infusion rate during the study,
whole-body net glucose utilization rates were greater
in IUGR-AR lambs (62 ± 4 µmol min−1 kg−1) than
in IUGR (50 ± 3 µmol min−1 kg−1) and control
lambs (51 ± 3 µmol min−1 kg−1; Fig. 5C). Endogenous
glucose production rates decreased from basal periods
(39 ± 2 µmol min−1 kg−1) when insulin was infused
at 2 mU min−1 kg−1 (18 ± 3 µmol min−1 kg−1) or
4 mU min−1 kg−1 (10 ± 3 µmol min−1 kg−1), but were
not different among groups for either insulin infusion
rate (Fig. 5D). There was a group by insulin infusion rate
interaction (P < 0.05) for insulin sensitivity (Fig. 5E);
under basal conditions, insulin sensitivity was greater in
IUGR-AR lambs than in control or IUGR lambs. During
either hyperinsulinaemic period, insulin sensitivity was
lower than at basal conditions butwas not different among
all groups.
Hindlimb metabolic fluxes
Arterial blood oxygen content, plasma glucose and lactate
concentrations, and hindlimb oxygen uptake rates, lactate
output rates and nutrient oxygen quotients measured
during the hyperinsulinaemic–euglycaemic clamps are
presented in Table 3. No interaction between experimental
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groups and insulin infusion rates was observed for any
of these variables. Plasma glucose concentrations, blood
oxygen content andhindlimbnet oxygenuptake rateswere
not different among groups or at the two insulin infusion
rates. Plasma lactate concentrations were similar between
IUGR lambs (0.73± 0.08mmol l−1) and IUGR-AR lambs
(0.92 ± 0.08 mmol l−1) but were greater (P < 0.05)
than in control lambs (0.50 ± 0.07 mmol l−1). Hindlimb
lactate output rates and lactate oxygen quotients were not
different amonggroups or at the two insulin infusion rates.
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Figure 5. Whole-body glucose utilization rates
Hyperinsulinaemic–euglycaemic clamps were performed in control (n = 14; 8M/6F), IUGR (n = 14; 3M/11F) and
IUGR-AR (n = 7; 1M/6F) lambs at 28 days of age. Whole-body net glucose utilization rates were measured at
basal and two hyperglycaemic periods created with sequential increases in the insulin infusion rate (0, 2 and
4 mU min−1 kg−1), which are indicated on the x-axis. Experimental group means ± SEM are presented for blood
glucose concentrations (A), plasma insulin concentrations (B), body weight-specific glucose utilization rates (C),
endogenous glucose production rates (D) and insulin sensitivity (E). Main effects in the two-way ANOVA included
experimental group, study period for the insulin infusion rate, and their interaction (group by period). P values
are presented for these effects if they were significant (P  0.05). For an interaction, differences (P  0.05) are
identified by different letters.
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Hindlimb glucose utilization rates were not different
between IUGR and IUGR-AR lambs (28.4 ± 2.9 and
28.6 ± 3.0 µmol min−1 kg−1, respectively), but hind-
limb glucose utilization rates in both experimental
groups were greater (P < 0.05) than control lambs
(19.8 ± 2.5 µmol min−1 kg−1), regardless of the
insulin infusion rate (Fig. 6A). Across all groups, hind-
limb glucose utilization rates increased from basal
(18.9 ± 1.9 µmol min−1 kg−1) to hyperinsulinaemic
periods when insulin was infused at 2 mU min−1 kg−1
(25.9 ± 1.9 µmol min−1 kg−1) and 4 mU min−1 kg−1
(32.0 ± 3.0 µmol min−1 kg−1). This coincided with
greater glucose extraction efficiencies (4.5 ± 0.6%,
7.1 ± 0.6% and 10.4 ± 0.6% at basal, and 2 and
4 mU min−1 kg−1, respectively) and glucose oxygen
quotients (0.81 ± 0.11, 1.13 ± 0.11 and 1.59 ± 0.11
at basal, and 2 and 4 mU min−1 kg−1, respectively;
Table 3). Glucose extraction efficiencies, glucose oxygen
quotients, and glucose + lactate oxygen quotients were
not different among groups. However, glucose + lactate
oxygen quotient increased sequentially with higher insulin
infusion rates (0.58 ± 0.10, 0.89 ± 0.11, 1.34 ± 0.11 at
0, 2 and 4 mU min−1 kg−1). Hindlimb glucose oxidation
rates increased from basal (1.2 ± 0.4 µmol min−1 kg−1)
to subsequent periods when insulin was infused at
4 mU min−1 kg−1 (4.9 ± 0.4 µmol min−1 kg−1),
but were not different among groups during basal or
hyperinsulinaemic periods (Fig. 6B). However, hind-
limb fractional glucose oxidation rates were lower in
IUGR lambs (10.5 ± 1.4%) and IUGR-AR lambs
(9.7 ± 1.4%) than in control lambs (16.6 ± 1.2%)
regardless of insulin infusion rate (Fig. 6C). In all groups,
fractional glucose oxidation rates increased from basal
(6.7 ± 1.0%) to subsequent higher insulin infusion rates
(17.9 ± 1.0%).
Post-mortem organ weights
At necropsy body weight and brain, lung, liver, kidney,
heart, left ventricle, right ventricle and hindlimb weights
were less in IUGR and IUGR-AR lambs compared to
controls (Table 4). Brain and liver weights relative to
body weights were greater in IUGR and IUGR-AR lambs
compared to control lambs. Lung, kidney and right
ventricle weights relative to bodyweight were not different
among groups. Heart weight relative to body weight was
greater in IUGR-AR lambs than in IUGR and control
lambs, and relative left ventricle weight was greater in
IUGR-AR lambs than controls.
In vitro pancreatic islet insulin secretion
Pancreatic islet viability assessed by OCR/DNA was not
different between control (387 ± 23 nmol O2 min−1 (mg
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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DNA)−1) and IUGR lambs (396± 43 nmol O2 min−1 (mg
DNA)−1). Islets from IUGR and IUGR-AR lambs had
reduced first-phase and second-phase GSIS compared to
islets from control lambs (Fig. 7). IUGR and IUGR-AR
GSIS response was similar. Islets from IUGR lambs also
had less insulin content compared to control islets, but
IUGR-AR islets were not different among groups.
Ex vivo skeletal glucose oxidation rates
There was an interaction (P< 0.05) between experimental
groups and incubation media for ex vivo glucose
oxidation rates in primary myofibres. Glucose oxidation
rates of muscle fibres from control lambs were
25 ± 5 pmol mg−1 h−1 greater in media with
insulin compared to basal media without insulin
(Fig. 8). Inclusion of cytochalasin B (glucose transport
inhibitor) or catecholamines to insulin-supplemented
media decreased insulin-stimulated glucose oxidation
rates in muscle fibres from controls to rates that
were below those observed in basal media. Glucose
oxidation rates in basal media were not different between
IUGR and IUGR-AR muscle fibres but were lower
in both of these groups compared to control muscle.
Insulin-stimulated glucose oxidation rates were not
different between IUGR and IUGR-AR muscle fibres
but were 33 ± 6 and 27 ± 8 pmol mg−1 h−1 lower,
respectively, compared to controlmuscle fibres.Moreover,
insulin-supplemented media had no effect on glucose
oxidation rates in IUGR muscle fibres when compared
to rates in basal media, but insulin increased glucose
oxidation rates 18 ± 7 pmol mg−1 h−1 above basal rates
in IUGR-AR muscle fibres. Inclusion of cytochalasin B or
catecholamines in insulin-supplemented media reduced
glucose oxidation rates in IUGR and IUGR-AR muscle
fibres to rates that were not different from those observed
in basal media.
Skeletal muscle glycogen content and citrate
synthase activity
Glycogen content in the semitendinosus muscle was not
different among control (13.7 ± 1.2 mg g−1), IUGR
(15.3 ± 1.1 mg g−1) and IUGR-AR (11.9 ± 1.2 mg g−1)
groups. Citrate synthase activities were not different
between semitendinosus muscles from control
(343 ± 13 µmol min−1 (mg protein)−1) and IUGR lambs
(348 ± 12 µmol min−1 (mg protein)−1) but were lower
(P < 0.05) in IUGR-AR lambs (287 ± 15 µmol min−1
(mg protein)−1) compared to control or IUGR lambs.
Glucose transporters, insulin receptor and ADRβ2 in
muscle
GLUT1 concentrations in the semitendinosusmusclewere
not different between control and IUGR lambs or between
IUGR and IUGR-AR lambs but were greater (P < 0.05) in
IUGR-AR lambs compared to control lambs (Fig. 9A).
GLUT4 concentrations were lower (P < 0.05) in the
semitendinosus muscle from IUGR and IUGR-AR lambs
than in control lambs (Fig. 9B). Protein concentrations
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Figure 6. Hindlimb glucose fluxes
Hindlimb weight-specific net glucose utilization rates (A), glucose oxidation rates (B) and fractional glucose
oxidation (C) were measured in control (n = 7; 3M/4F), IUGR (n = 5; 1M/4F) and IUGR-AR (n = 5;
1M/4F) lambs. Rates of glucose utilization across the hindlimb were determined at three steady-state periods:
basal (0 mU min−1 kg−1) and two hyperinsulinaemic periods produced with insulin infusion rates at 2 and
4 mU min−1 kg−1 (x-axis). Glucose oxidation and fractional glucose oxidation rates were evaluated at basal and
4 mU min−1 kg−1 infusion periods. Main effects in the two-way ANOVA included experimental group, study
period for the insulin infusion rate and their interaction (group by period). P values are presented on the graph if
the effects were significant (P  0.05).
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Table 4. Post-mortem organ weights
Group (n) Control (15) IUGR (14) IUGR-AR (7)
Body weight (kg) 13.1 ± 0.6a 8.9 ± 0.6b 7.3 ± 0.8b
Brain (g) 73 ± 2a 64 ± 2b 62 ± 3b
Lung (g) 229 ± 11a 163 ± 12b 127 ± 16 b
Liver (g) 342 ± 15a 251 ± 15b 225 ± 21b
Average kidney (g) 40.3 ± 1.8a 30.3 ± 1.8b 25.6 ± 2.6b
Heart (g) 82 ± 4a 56 ± 4b 56 ± 6b
Right ventricle (g) 17.8 ± 1.0a 11.7 ± 1.0b 10.2 ± 1.4b
Left ventricle (g) 30.9 ± 1.7a 22.3 ± 1.9b 20.6 ± 2.5b
Hindlimb (kg) 1.20 ± 0.06a 0.80 ± 0.05b 0.68 ± 0.08b
Relative brain weight (g kg−1)† 5.6 ± 0.5a 7.8 ± 0.5b 9.6 ± 0.8b
Relative lung weight (g kg−1)† 17.5 ± 0.7 18.8 ± 0.7 18.0 ± 1.0
Relative liver weight (g kg−1)† 26.1 ± 0.9a 29.0 ± 0.9b 31.7 ± 1.3b
Relative kidney weight (g kg−1)† 3.1 ± 0.2 3.5 ± 0.2 3.8 ± 0.3
Relative heart weight (g kg−1)† 6.2 ± 0.2a 6.3 ± 0.2a 7.8 ± 0.3b
Relative left ventricle weight (g kg−1)† 2.4 ± 0.1a 2.6 ± 0.1ab 2.8 ± 0.2b
Relative right ventricle weight (g kg−1)† 1.4 ± 0.1 1.3 ± 0.1 1.4 ± 0.1
Data are expressed as the mean ± SEM. Differences (P < 0.05) between groups are identified with different superscript letters.
†Relative to body weight.
for ADRβ2 and INSR were not different among groups
(Fig. 9C and D).
Discussion
Previous work has shown that IUGR fetal sheep produced
by placental insufficiency develop disparities in insulin
secretion, skeletal muscle growth and glucose metabolism
in late gestation (Limesand et al. 2006, 2007; Brown
et al. 2015; Yates et al. 2016). In this study, we show
that the disruption in pancreatic islet insulin secretion
and skeletal muscle glucose metabolism persisted in
1-month-old lambs that were born following placental
insufficiency-induced IUGR, despite normal whole-body
glucoseutilization rates and insulin sensitivity. Specifically,
we found that GSIS, which is enhanced in IUGR lambs
at earlier ages (Camacho et al. 2017), was reduced at
1 month of age despite normal plasma catecholamine
concentrations at this age. Reductions in insulin secretion
responsiveness in IUGR lambs were associated with less
islet insulin content,which indicates a diminished capacity
for their β-cells to synthesize and store insulin, similar
to the IUGR fetus (Limesand et al. 2006). Additionally,
the IUGR hindlimb glucose utilization rates were higher
than normal but the fractional glucose oxidation rates
were lower. Studies in primary muscle fibres from IUGR
lambs further showed that the muscle-specific glucose
oxidative capacity was impaired. Postnatal manipulation
of β adrenergic receptor activity via daily oral treatment
withADRβ2 agonist andADRβ1/β3 antagonists improved
whole-body glucose utilization rates and basal insulin
sensitivity in IUGR lambs. However, the treatment had
no effect on their hindlimb glucose metabolism or
skeletal muscle glucose oxidation rates. This coincided
with equivalent skeletal muscle expression of ADRβ2 and
insulin receptor β among all groups. Unexpectedly, IUGR
lambs also had faster heart rates that were independent of
ADRβ1 activation because postnatal ADRβ1 antagonists
did not slow heart rates in IUGR-AR lambs. The findings
from this study show that changes in β adrenergic activity
underlie some but not all postnatal outcomes of IUGR
produced by placental insufficiency and that multiple
mechanisms contribute to the programming of metabolic
dysfunction in the IUGR lambs.
Neonatal growth
At birth, IUGR lambs weighed less than controls
and had asymmetric fetal growth restriction, which is
consistent with fetal growth patterns and birth metrics for
pathological IUGR human infants (Riyami et al. 2011).
IUGR lambs had greater head circumference-to-birth
weight ratios that indicate fetal brain sparing, which was
confirmedatnecropsy.This asymmetrywas comparable to
the ovine endometrial carunclectomy model of placental
restriction (De Blasio et al. 2006, 2007; Owens et al.
2007bb; Morrison, 2008; Liu et al. 2015). We attribute
the asymmetric growth in our IUGR lambs to the
progressive rise in circulating fetal catecholaminesbrought
on by placental insufficiency-induced hypoxaemia and
hypoglycaemia (Macko et al. 2013, 2016; Davis et al.
2015). Although not measured in the present study, it is
reasonable to assume that our IUGR lambs were exposed
to chronically elevated concentrations of catecholamines
in utero, as shown previously (Limesand et al. 2006, 2013).
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Infants with fetal growth restriction typically
exhibit accelerated early-life growth velocity, which
independently predicts their risk for developingmetabolic
disease (Barker et al. 2002; Dulloo, 2006; Claris et al.
2010). Driven by greater fat deposition, early catch-up
growth is associated with greater central obesity, insulin
resistance and cardiovascular disease in humans (Jaquet
et al. 2000; Gluckman et al. 2008; Ibanez et al. 2008). In
other sheep models of IUGR, longitudinal studies show
that IUGR lambs reach normal body weights by 1 month
of age (De Blasio et al. 2006; Liu et al. 2015; Spiroski et al.
2018). However, greater central adiposity at 6 weeks of age
indicates that a larger percentage of their early weight gain
is due to fat deposition, even though body composition
normalized in adulthood (Liu et al. 2015). Similarly,
the over-nourished adolescent model of IUGR exhibited
greater daily weight gain and adiposity near weaning, but
their body composition normalized later (Wallace et al.
2018; Wallace, 2019). Unlike the other ovine models, our
IUGR lambs had similar fractional growth rates through
the first 30 days. The reason for the absence of catch-up
growth is not clear, but it is unlikely that it was due to
insufficient postnatal nutrition. After colostrum, all lambs
were fed similar amounts of commercial milk replacer
to minimize nutrient variability from heat stressed ewes
(Abdalla et al. 1993). The average daily gain for our control
lambs was comparable to those reported in lambs reared
by the ewe (Louey et al. 2000; De Blasio et al. 2006; Liu
et al. 2015; Wallace et al. 2018). The lack of early-stage
catch-up growth is in fact a major benefit of this model
and studybecause early catch-upgrowthmaycontribute to
metabolic deficits in some cases.Herewe demonstrate that
metabolic deficits can occur in the absence of confounding
early catch-up growth. Therefore, despite the absence of
confounding catch-up growth in our IUGR lambs, defects
in β-cell function and skeletal muscle glucose metabolism
were apparent, which reflect developmental programming
due to the in utero environment.
The lack of improved growth performance in IUGR
lambs treated with clenbuterol was unexpected based
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Figure 7. Isolated islet insulin secretion responsiveness to glucose
Dynamic measurements of glucose-stimulated insulin secretion were analysed in islets isolated from control (n = 4;
2M/2F), IUGR (n = 3; 1M/2F) and IUGR-AR (n = 3; 0M/3F) lambs. A, insulin secretion rates (pg min−1 (µg DNA)−1)
are shown at the time collected. Stimulatory glucose concentrations (11.1 mmol l−1) were initiated at 3 min, which
is indicated by the grey arrow. B, area under the curve (AUC) for 3–11 min was calculated for each experimental
group to measure first-phase insulin secretion. C, AUCs for second-phase insulin secretion (12–40 min) are
presented. D, islet insulin contents were measured. Differences (P < 0.05) between experimental groups are
indicated by different letters.
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
16 D. T. Yates and others J Physiol 00.0
on previous findings in older lambs (Beermann et al.
1987; Bohorov et al. 1987). Beermann (2002) post-
ulated that this unresponsiveness to an ADRβ2 agonist
in young lambs is caused by either low skeletal muscle
sensitivity to ADRβ2 or the growth rate is already near the
maximum for skeletal muscle at this age. Our findings
are inconsistent with ADRβ2 insensitivity because we
found greater whole-body glucose utilization rates and
insulin sensitivity in IUGR-AR lambs. However, if the
latter is true and muscle growth is near maximum,
repartitioning of nutrients with ADRβ2 would not
be effective. Furthermore, younger, less physiologically
mature animals have lower rates of lipid accretion
than mature animals, which also lowers ADRβ2 agonist
effectiveness (Williams et al. 1987; Maltin et al. 1990).
Alternatively, the growth rates exhibited in our IUGR
lambs may be indicative of a lower capacity for muscle
accretion, as previously observed (Yates et al. 2014, 2016;
Soto et al. 2017).
Insulin secretion
At 1 month of age, IUGR lambs exhibited substantially
impaired first- and second-phase GSIS. Concurrent
deficits in both phases of secretion are indicative of
glucose intolerance, which frequently progresses with age
to a diabetic state that is characterized by complete loss
of the first-phase secretion and further decline of the
second-phase secretion (Gerich, 2002; Seino et al. 2011).
Lower GSIS by 1 month of age is a stark difference to the
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Glucose oxidation rates were measured in semitendinosus muscle
fibres from control (n = 12; 8M/4F), IUGR (n = 13; 3M/10F) and
IUGR-AR (n = 6; 1M/5F) lambs. Rates of glucose oxidation were
determined in four media conditions containing no hormones
(basal), 10 µU ml−1 insulin, insulin (10 µU ml−1) + catecholamines
(12.5 µmol l−1 adrenaline and 12.5 µmol l−1 noradrenaline) and
insulin (10 µU ml−1) + 20 mmol l−1 cytochalasin B. Differences
(P  0.05) are identified by different letters above the bars
(means ± SEM).
compensatory enhancement of GSIS that we previously
observed in IUGR lambs at 1 week of age. In fetal sheep,
placental insufficiency is associated with lower insulin
secretion as early as 0.7 of gestation, which is prior to
the onset of fetal growth restriction (Limesand et al. 2013;
Macko et al. 2013). Blunted insulin secretion continues
throughout the remainder of gestation and is inhibited
in part by high concentrations of plasma catecholamines
(Owens et al. 2007a; Leos et al. 2010; Macko et al.
2016). In fact, similar inhibition occurred when hyper-
catecholaminaemia was induced in normally grown
fetuses with an exogenous noradrenaline infusion (Chen
et al. 2014), acute maternofetal hypoxia (Jackson et al.
2000; Yates et al. 2012b), anaemic hypoxaemia (Benjamin
et al. 2017), or insulin imbalance (Andrews et al. 2015).
Interestingly, an acute adrenergic blockade in the IUGR
fetus revealed the development of this hyper-insulin
secretion response (Leos et al. 2010; Macko et al. 2013).
This compensatory enhancement of insulin secretion
develops in opposition to chronic adrenergic stimulation,
because we also observed hypersecretion in fetal sheep
immediately after stopping a week-long infusion of
noradrenaline that was still present 5 days after the
infusion was terminated (Chen et al. 2014, 2017). Primary
islets fromnoradrenaline-infused fetuses exhibited greater
GSIS in vitro. These islets had normal insulin content,
calcium signalling and morphology but showed evidence
of adrenergic desensitization, which now appears to be the
mechanism for compensatory insulin stimulus–secretion
coupling (Chen et al. 2017; Kelly et al. 2018).
Additionally, GSIS remained augmented in placental
insufficiency-induced, overnourished adolescent-induced
and twinning-induced IUGR lambs for more than a
week after birth (Gatford et al. 2013; Camacho et al.
2017; Wallace et al. 2018), which helps to explain the
dangerous condition of transitional hyperinsulinaemic
hypoglycaemia that frequently afflicts newborns with
IUGR (Stanley et al. 2015; Rozance & Hay, 2016).
Our study shows that the compensatory enhancement
of insulin secretion is a transient condition that subsides
after the first few weeks of life to reveal programmed
deficits in β-cell function. Perfusion studies recapitulate
the poor insulin secretion response of IUGR islets to
glucose, demonstrating that the impairment is intrinsic
to the β-cells. In addition to lower insulin secretion
responsiveness, the capacity of the IUGR islets to
synthesize and store insulin was reduced, a deficiency
that was shown previously in fetal sheep with placental
insufficiency-induced IUGR (Limesand et al. 2006).
Although adrenergic dysregulation was shown to affect
fetal islets with IUGR, daily administration of ADRβ
modifiers did not improve islet response to glucose in
IUGR lambs.However, therewas amodest recovery in islet
insulin content, which may reflect lower insulin demands
due to the improved insulin sensitivity in IUGR-AR lambs
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(Leos et al. 2010; Kelly et al. 2018). These findings show
that pancreatic islet dysfunction persists after birth due
to limited insulin production and storage in IUGR islets,
even though there is hyper-insulin secretion at earlier ages.
Insulin action on tissues
Whole-body glucose utilization rates were similar between
control and IUGR lambs. Thus, data from both groups
were pooled to construct dose–response curves for
insulin-stimulated glucose utilization, which were used
to identify half-maximal insulin sensitivity (ED50) and
maximum insulin responsiveness as previously described
(Kahn, 1978). Half-maximal insulin sensitivity at 1month
of age was comparable to that observed in non-pregnant
adult ewes (Bergman et al. 1989; Petterson et al. 1993).
Although neonatal ED50 was similar to adult ewes,
maximum insulin responsiveness was about fourfold
greater in lambs, which is consistent with the previously
observed progressive decline in insulin action as sheep
advance in age (Gatford et al. 2004).
We previously found that whole-body glucose
utilization rates were greater in IUGR lambs at 2 weeks
of age (Camacho et al. 2017). In this study, similar
whole-body glucose utilization rates between control and
IUGR lambs indicate that a correction in whole-body
insulin action for glucose occurs by 1 month of age.
Furthermore, hepatic glucose production rates did not
differ between control and IUGR lambs at 2 weeks
(Camacho et al. 2017) or 1 month of age, even though
plasma lactate concentrations were higher in IUGR lambs
at both ages. The correction in whole-body insulin action
was not explained by hindlimb glucose fluxes or skeletal
muscle glucose transporter profiles. Hindlimb glucose
utilization rates were greater in IUGR lambs under basal
and hyperinsulinaemic conditions, despite less GLUT4
and similar GLUT1 concentrations in skeletal muscle.
Interestingly, there was no difference in GLUT1 or GLUT4
concentrations between control and IUGR skeletal muscle
near term (Limesand et al. 2007) or at 2 weeks of age
(Camacho et al. 2017). Therefore, muscle adaptations
responsible for increased insulin sensitivity appear to be
independent of the expression of these glucose trans-
porters, but could involve the translocation of GLUT4 to
the plasma membrane. Furthermore, these data indicate
that compensatory changes in glucose uptake by other
tissuesmight help to normalize glucose tolerance in IUGR
lambs. These findings show continuing changes in glucose
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Figure 9. Glucose transporters, insulin receptor
and adrenergic receptor β2 expression in
skeletal muscle
Protein expression levels of GLUT1 (A), GLUT4 (B),
ADRβ2 (ADRB2; C) and insulin receptor β (INSR; D)
were measured in semitendinosus muscle from
control (n = 8; 4M/4F), IUGR (n = 8; 3M/5F) and
IUGR-AR (n = 7; 1M/6F) lambs. Representative
images of western blots are shown for the glucose
transporters and receptors and β-Tubulin (TUBB),
which was used for normalization. Means ± SEM
are presented in the bar graphs and differences
(P < 0.05) are indicated with different letters.
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metabolism of IUGR lambs over the first month of life,
although it is unclearwhether changes in insulin sensitivity
will ultimately progress into glucose intolerance as in other
models (Ford et al. 2007; Owens et al. 2007b).
Whole-body insulin sensitivity and glucose utilization
rates were greater in IUGR lambs treated with β
adrenergic modifiers. Across all insulin concentrations,
whole-body glucose utilization rates were 23%
higher in IUGR-AR lambs compared to both control
and IUGR lambs. This coincided with greater
hindlimb-specific glucose utilization rates and skeletal
muscle GLUT1 concentrations compared to control
lambs. However, neither glucose utilization rates nor
GLUT1 concentrations differed from untreated IUGR
lambs, which indicates contributions from other
mechanisms. In adult humans and rats, chronic
administration of ADRβ2 agonists increased insulin
sensitivity for non-oxidative glucose utilization and lactate
production but not glycogen synthesis (Scheidegger et al.
1984; Budohoski et al. 1987; Jensen et al. 2005). A
subsequent study of post-receptor interactions between
insulin and β adrenergic signalling pathways via acute
ex vivo treatments found that protein kinase A and
protein kinase B (AKT) regulate distinct pools of glycogen
synthase kinase-3α/β that are separated by locale within
the cell or by the niche of co-activators (Jensen et al. 2007).
We previously found that co-incubation of rat soleus with
insulin and ADRβ2 agonist for 1 h had an additive effect
on AKT phosphorylation, although ADRβ2 agonist in the
absence of insulin had no effect on AKT phosphorylation
and in fact lowered glucose uptake (Cadaret et al.
2017). Additive post-receptor effects may help to explain
differences in acute ex vivo insulin-stimulated glucose
oxidation, but reduced citrate synthase activity associated
with β adrenergic modifiers in our IUGR lambs indicate
potentially reduced mitochondrial density and other
detrimental metabolic changes.
Fractional glucose oxidation rates are lower in IUGR
fetal sheep near term (Limesand et al. 2007; Brown
et al. 2015), which we have postulated is due to skeletal
muscle-specific programming aimed at nutrient sparing
(Yates et al. 2012a, 2018). In this study, we found
that impaired glucose oxidative capacity was indeed
muscle-specific and persisted in IUGR lambs at 1 month
of age, but was not improved by postnatal β adrenergic
modifiers. Hindlimb-specific glucose utilization rates
in IUGR lambs were greater than normal across a
range of insulin concentrations, but the proportion of
glucose utilized by hindlimb tissues for oxidation was
diminished. Moreover, primary hindlimb skeletal muscle
had lower ex vivo glucose oxidation rates under basal and
insulin-stimulated incubation conditions. These results
demonstrate that insulin sensitivities for non-oxidative
and oxidative glucose metabolism differ in skeletal muscle
of IUGR lambs similar to whole-body glucosemetabolism
in the IUGR fetus (Limesand et al. 2007; Brown et al.
2015). For IUGR fetuses, this could be at least partially
explained by enhanced insulin signalling pathways, as
IUGR fetal muscle expresses greater insulin receptor β
and less p85α (Thorn et al. 2009). In IUGR lambs,
however, skeletalmuscle insulin receptorβ concentrations
were not affected at 2 weeks (Camacho et al. 2017)
or 1 month of age (present study). Moreover, normal
skeletal muscle citrate synthase activity in IUGR lambs
indicates that diminished oxidative metabolic capacity
is not due to reduced mitochondrial density. Rather, it
may be due to altered pyruvate metabolism or impaired
mitochondrial oxidative phosphorylation, as suggested by
previous studies (Brown et al. 2015; Kelly et al. 2017;
Pendleton et al. 2019). Equivalent lactate output, nutrient
quotients and skeletal muscle glycogen content among all
of our lambs indicates that the lower fractional glucose
oxidation was not offset by greater glycolytic rates and
glucose storage. Hindlimb glucose and lactate fluxes in
IUGR fetal sheep further indicate that faster glycolytic
rates are not a component of IUGR skeletal muscle
programming (Rozance et al. 2018). Thus, additional
studies will be needed to characterize the mechanisms
responsible for the programmed defects in skeletal muscle
glucose metabolism demonstrated by this study.
Cardiovascular response
The chief aim ofmeasuring the cardiovascular response in
the present study was to determine the in vivo functional
presence of the orally administered ADRβ modifiers.
ADRβ1 agonist dobutamine increased the heart rate in
both control and IUGR group, albeit to a lesser extent,
but was unable to produce any change in the heart rate
of the lambs in IUGR-AR group. This demonstrates
the functional presence of orally administered ADRβ1
antagonist atenolol. Unexpectedly, the treatment of
ADRβ modifiers increased the relative size of the heart,
specifically the left ventricle, which may indicate that
the hypertrophy was from direct adrenergic regulation
or from indirect adrenergic alteration of systemic blood
pressures. The direct adrenergic mechanism may be in
response to ADRβ2 activation and ADRβ1 inhibition to
lower cardiomyocyte apoptosis via phosphoinositide 3
kinase and AKT pathways (Communal et al. 1999; Chesley
et al. 2000; Gu et al. 2000; Zaugg et al. 2000; Zhu et al.
2001). In humans, IUGR is associated with greater risk for
cardiovascular pathologies including hypertension, tachy-
cardia and irregular cardiac growth (Brodszki et al. 2005;
Crispi et al. 2010; Zanardo et al. 2011; Spence et al. 2012;
Bjarnegard et al. 2013; Gaillard et al. 2013; Chatmethakul
& Roghair, 2019). From this experiment, we show that
heart rates were faster in IUGR lambs irrespective of the
postnatal treatment and that the hearts from IUGR lambs
were less responsive to the ADRβ1 agonist dobutamine.
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These findings warrant further investigation of ADRβ1
responsiveness and other factors regulating heart rate.
Conclusion
Present findings allow us to conclude that metabolic
pathologies in offspring that were born with IUGR
manifest very early after birth and are the product
of adaptive programming involving multiple tissues.
Enhanced insulin secretion responsiveness to glucose is
present in IUGR lambs at 1 week of age but subsides
by 4 weeks of age, at which time β-cell dysfunction
is apparent. Whole-body insulin sensitivity, which is
also greater in the near-term IUGR fetus and lamb at
2 weeks of age, had normalized by 1 month of age.
However, disparities in skeletal muscle-specific glucose
metabolism persisted in lambs with IUGR. These include
higher hindlimb glucose utilization rates that may
be required to compensate for oxidative deficiencies
of glucose in primary IUGR myocytes, thus causing
fractional glucose oxidation rates to be lower in the
hindlimb. Although the inherent discrepancies between
glucose uptake and oxidation in muscle were unresolved
by lactate release and glycogen content, greater trans-
amination of pyruvate to alanine has been described in
muscle of the IUGR fetus, which, if persistent,may explain
the deficiencies in carbohydrate metabolism (Chang
et al. 2019). Alternatively, the myocyte deficiencies in
insulin-stimulated glucose oxidation indicate that other
factors contribute to glucose metabolism in vivo. We
postulated that disrupted β adrenergic signalling plays
an underlying role in the development of metabolic
defects based on previously observed chronic hyper-
catecholaminaemia in the IUGR fetus. However, daily oral
supplementation of pharmaceuticals intended to target
suspected β adrenergic changes resulted in only modest
improvements in insulin-sensitive glucose metabolism
and did not improve deficits in islet GSIS or skeletal
muscle glucose metabolism in IUGR lambs. Moreover,
targeted β adrenergic modifications did not improve the
increased basal heart rates observed in IUGR lambs.
Together, this study provides new insights regarding β-cell
dysfunction and muscle-specific adaptations that pre-
dispose neonates that were born with IUGR to later life
metabolic dysfunction.
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